Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid

doi:10.1016/0009-8981(91)90070-S

Clinica Chimica Acta

Volume 196, Issues 2–3, 15 February 1991, Pages 167-176

https://doi.org/10.1016/0009-8981(91)90070-S Get rights and content

Abstract

Apolipoprotein E was measured in paired sera and cerebrospinal fluid samples from 483 neurological patients. The average apolipoprotein E concentration was 7.5 (±3.1) mg/l in cerebrospinal fluid and 93.5 (±29.7) mg/l in serum. Mean apolipoprotein B concentrations in 88 patients were 0.77 ± 3.4 mg/l in cerebrospinal fluid and 1.06 ± 0.31 g/l in serum. The apolipoprotein E concentration in cerebrospinal fluid was much greater than expected for passive diffusion from serum. By contrast to apolipoprotein B, there was no correlation between the apolipoprotein E cerebrospinal fluid/serum concentration quotient and the albumin concentration quotient. This suggests that apolipoprotein E in cerebrospinal fluid, unlike apolipoprotein B, is locally synthesized and that the use of a cerebrospinal fluid/serum concentration quotient is unnecessary.

In a control group (n = 64) the mean cerebrospinal fluid apolipoprotein E value (± SD) was 5.9 (1.6) mg/l. Elevated cerebrospinal fluid apolipoprotein E concentrations were observed in acute (n = 22, 12.5 ± 6:2 mg/l) and chronic inflammatory central nervous system diseases (n = 15, 10.4 ± 2.4 mg/l).

References (19)

RW Mahley et al.
Plasma lipoproteins: apolipoprotein structure and function
J Lipid Res
(1984)
DM Driscoll et al.
Extrahepatic synthesis of apolipoprotein E
J Lipid Res
(1984)
RE Pitas et al.
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Biochim Biophys Acta
(1987)
RE Pitas et al.
Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain
J Biol Chem
(1987)
H Reiber et al.
Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system
Clin Chim Acta
(1987)
G Stoll et al.
Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve
Glia
(1989)
RW Mahley
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology
Science
(1988)
GJ Snipes et al.
Nerve injury stimulates the secretion of apolipoprotein E by non-neural cells
HW Müller et al.
A specific 37000-Dalton protein that acumulates in regenerating but not in non-regenerating mammalian nerves
Science
(1985)

There are more references available in the full text version of this article.

Cited by (92)

Cholesterol metabolism: Towards a therapeutic approach for multiple sclerosis
2023, Neurochemistry International
Growing evidence points to the importance of cholesterol in preserving brain homeostasis. Cholesterol makes up the main component of myelin in the brain, and myelin integrity is vital in demyelinating diseases such as multiple sclerosis. Because of the connection between myelin and cholesterol, the interest in cholesterol in the central nervous system increased during the last decade. In this review, we provide a detailed overview on brain cholesterol metabolism in multiple sclerosis and its role in promoting oligodendrocyte precursor cell differentiation and remyelination.
CSF ApoE predicts clinical progression in nondemented APOEε4 carriers
2017, Neurobiology of Aging
Citation Excerpt :
In addition to mechanisms directly related to pathophysiological processes in the brain, the APOEε4 genotype could also increase risk of dementia due to AD by influencing cardiovascular risk (Caselli and Reiman, 2013; Holtzman et al., 2012; Kester et al., 2010; Mahley and Rall, 2000). If this is the case, plasma ApoE may be a better reflection of this mechanism in vivo than CSF ApoE, because the 2 are not correlated and it is therefore likely that plasma ApoE is derived from a peripheral source (the liver), while CSF ApoE is derived from the brain (Baker-Nigh et al., 2016; Carlsson et al., 1991; Cruchaga et al., 2012; Fagan et al., 2000). Our finding that plasma ApoE did not predict clinical progression while CSF ApoE did, could imply that the activity of ApoE in the brain determines the risk of developing dementia due to AD to a larger extent than its cardiovascular effects.
Possible associations between cerebrospinal fluid (CSF) and plasma apolipoprotein E (ApoE) concentration and early clinical and pathophysiological manifestation of Alzheimer's disease were studied in a large and well-defined population of nondemented patients. CSF and plasma ApoE concentrations were related to CSF Aβ42, Tau and pTau levels and clinical characteristics in patients with subjective cognitive decline (n = 207) or mild cognitive impairment (n = 213) aged 64.2 ± 9.0 years, with a 2.5 ± 1.5 years follow-up. A 1 standard deviation increase in log-transformed CSF ApoE concentrations increased the risk of clinical progression in APOEε4 carriers 1.5 times (hazard ratio [95% confidence interval] 1.5 [1.1–2.0]), while this was not the case in APOEε4 noncarriers (hazard ratio [95% confidence interval] 1.0 [0.8–1.2]). Plasma ApoE did not predict clinical progression. Using linear regression models, strong associations between CSF ApoE levels and CSF Tau (β 0.51 [0.38–0.65]) and pTau (β 0.53 [0.40–0.60]) values were observed in APOEε4 carriers. We hypothesize CSF ApoE4 increases risk of clinical progression through its association with CSF Tau in APOEε4 carriers. Development of Alzheimer's disease in APOEε4 noncarriers may be unrelated to ApoE concentration.
Redox status of serum apolipoprotein E and its impact on HDL cholesterol levels
2017, Clinical Biochemistry
Citation Excerpt :
This finding indicated that this method would allow us to determine the number of cysteine residues in the target protein by estimating the extent of mobility shift. The reason for the inconsistency between the apparent and actual molecular weight is that the PEG molecule is hydrated extensively, as demonstrated previously [29,30]. In accordance with the number of cysteine residues, recombinant apoE3 showed a mobility shift equivalent to labeling with one PEG-PC-Mal moiety (PEG-PC-Mal)1, and recombinant apoE4, which possesses no cysteine, showed no mobility shift.
Apolipoprotein E (apoE) is closely involved in the pathogenesis of apoE-related diseases, such as Alzheimer's disease and cardiovascular disease. The redox modulation of cysteine-thiols in a protein is involved in various pathophysiological regulations; however, that of apoE has not been studied in detail. Herein, we devised an analytical method to determine the redox status of serum apoE and assessed its relation to serum cholesterol levels and apoE phenotype.
The present method was based on a band shift assay, using a photocleavable maleimide-conjugated polyethylene glycol.
The basic characteristics of the present method were found to be satisfactory to determine the redox status of serum apoE quantitatively. Serum apoE was separated into its reduced-form (r-), non-reduced-form (nr-), apoE-AII complex, and homodimer using this method. R-apoE could be detected as a 40-kDa band, whereas nr-apoE remained as monomeric apoE. R-apoE displayed a preference for VLDL; however, the levels showed the correlation with HDL-cholesterol levels (p < 0.005). Redox status of serum apoE was significantly different among apoE phenotypes. The quantitative ratios of nr-apoE to total apoE in serum from subjects with apoE4/E3 were higher than in serum from subjects with apoE3/E3 (p < 0.0001) and apoE3/E2 (p < 0.001).
The redox status of serum apoE might be related to the synthesis of HDL. The information concerning the redox status of serum apoE provided by the present method may be a potent indicator to evaluate various apoE-related diseases.
Cholesterol and markers of cholesterol turnover in multiple sclerosis: Relationship with disease outcomes
2016, Multiple Sclerosis and Related Disorders
Citation Excerpt :
ApoB is a major component of low density lipoprotein (LDL), intermediate density cholesterol (IDL) and very low density cholesterol (VLDL), and composes 95%, 60%, and 30% of their protein content, respectively (Ginsberg, 1998). LDL, IDL, and VLDL and ApoB are synthesized exclusively in the periphery and cannot pass through an intact blood-brain barrier (BBB; Carlsson et al., 1991; Di Paolo and Kim, 2011). ApoA1 and ApoA2 are major components of high-density lipoprotein (HDL), consisting of 70–80% and 10–15% of its protein mass, respectively (Ginsberg, 1998).
Multiple sclerosis (MS) is a chronic central nervous system disease that is associated with progressive loss of myelin and subsequent axonal degeneration. Cholesterol is an essential component of mammalian cellular and myelin membranes. In this systematic review, we examined the relationship between levels of cholesterol and markers of cholesterol turnover in circulation and/or cerebrospinal fluid (CSF) and disease outcomes in adults with clinically isolated syndrome (CIS) or confirmed MS. Studies suggest that elevated levels of circulating low density lipoprotein cholesterol (LDL), total cholesterol, and particularly, apolipoprotein B and oxidized LDL are associated with adverse clinical and MRI outcomes in MS. These relationships were observed as early as CIS. The studies also suggest that oxysterols, cholesterol precursors, and apolipoprotein E may be markers of specific disease processes in MS, but more research is required to elucidate these processes and relationships. Taken together, the data indicate that cholesterol and markers of cholesterol turnover have potential to be used clinically as biomarkers of disease activity and may even be implicated in the pathogenesis of MS.
Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n = 669): A pilot assay for methionine-containing proteotypic peptides
2012, Molecular and Cellular Proteomics
Citation Excerpt :
The same influencing order is found for brain amyloid β accumulation across cognitively normal individuals as demonstrated by imaging studies (82–85). Thus, a large body of evidence converges on a pivotal role of ApoE in the neurodegeneration process associated with a possible disruption of ApoE levels in the cerebrospinal fluid (7, 86–95). This is reinforced by the recent article by Cramer et al. who demonstrated reduced Aβ plaque area and improved cognitive functions in a mouse model of AD after treatment by bexarotene, an agonist of nuclear receptors that transcriptionally regulates ApoE expression (96).
Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE ε2, ApoE ε3 and ApoE ε4 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE ε4 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the ε4 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n = 68) of heterozygous ε3ε4 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n = 669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.
Roles of extracellular chaperones in amyloidosis
2012, Journal of Molecular Biology
Citation Excerpt :
Furthermore, in SAP knockout mice, amyloid deposition is delayed, suggesting that it has a pro-amyloidogenic role in vivo.155 ApoE is a 34-kDa secreted protein that is found in human plasma at approximately 60–120 μg/mL and in CSF at around one-tenth of this concentration.175 In humans, there are three common alleles of the ApoE gene designated ɛ2, ɛ3 and ɛ4, which result in three heterozygous and three homozygous genotypes.176
Extracellular protein misfolding and aggregation underlie many of the most serious amyloidoses including Alzheimer's disease, spongiform encephalopathies and type II diabetes. Despite this, protein homeostasis (proteostasis) research has largely focussed on characterising systems that function to monitor protein conformation and concentration within cells. We are now starting to identify elements of corresponding systems, including an expanding family of secreted chaperones, which exist in the extracellular space. Like their intracellular counterparts, extracellular chaperones are likely to play a central role in systems that maintain proteostasis; however, the precise details of how they participate are only just emerging. It is proposed that extracellular chaperones patrol biological fluids for misfolded proteins and facilitate their clearance via endocytic receptors. Importantly, many amyloidoses are associated with dysfunction in rates of protein clearance. This is consistent with a model in which disruption to, or overwhelming of, the systems responsible for extracellular proteostasis results in the accumulation of pathological protein aggregates and disease. Further characterisation of mechanisms that maintain extracellular proteostasis will shed light on why many serious diseases occur and provide us with much needed strategies to combat them.

View all citing articles on Scopus

View full text

Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid

Abstract

J Lipid Res

J Lipid Res

Biochim Biophys Acta

J Biol Chem

Clin Chim Acta

Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve

Glia

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

Science

Nerve injury stimulates the secretion of apolipoprotein E by non-neural cells

A specific 37000-Dalton protein that acumulates in regenerating but not in non-regenerating mammalian nerves

Science